Answers are grounded in this paper and cite their sources.
Preclinical trial assesses MR001 and TMZ efficacy in metastatic melanoma using MagIC-PDX models, suggesting potential for patient-relevant therapies.
e14504 Background: Advanced melanoma remains therapeutically challenging due to drug resistance, metastasis, and an immunosuppressive tumor microenvironment (TME). Temozolomide (TMZ) has demonstrated antitumor effects in melanoma in combination regimes. MR001 is a CD4/TGF-β bispecific antibody, first-in-class and first-in-human drug (approved by NMPA, 2023LP01942), which simultaneously activates CD4⁺ T cells and inhibits TGF-β signaling, reprogramming TME by limiting Treg-mediated immunosuppression, facilitating antitumor immune response, and increasing drug permeability. Conventional PDX is a powerful translational tool, but it has a low success rate, a lengthy establishment time, and requires high cost. Our previous studies proved that Magnetically-Induced Cell (MagIC) technology can expedite the reconstruction of the TME and the establishment of PDX (MagIC-PDX). This study aims to assess the efficacy of MR001 + TMZ in advanced metastatic melanoma in MagIC-PDX models. Methods: Metastatic melanoma MagIC-PDX models were established using NSG mice (n = 12) from fresh sample donated by a multiple metastatic melanoma patient in our hospital. In parallel, a murine model with humanized CD4⁺ (hCD4) mice (n = 32) were randomized into four groups: control, TMZ, MR001, and MR001 + TMZ; according to the patient all mice were engrafted with magnetized GFP/luciferase-labeled B16F10-GL cells into bone, subcutaneous tissue, and peritoneum using MagIC technology. Treatment was administered for 2 weeks along with bioluminescence imaging. TME remodeling was analyzed by immunofluorescence and qPCR. Concordance between the MagIC-PDX model and the corresponding patient clinical features was assessed. Results: In MagIC murine metastasis models, tumors developed at (3.9 ± 1.79) days. In the MR001 + TMZ group, both metastatic tumor size, qPCR, and bioluminescence signal are significantly decreased compared with both monotherapy groups (P < 0.001) and the control group (P < 0.001). Pathological examination showed that immunofluorescence signals of type III collagen encapsulation and decreased tumoral cell presence in the MR001 + TMZ group (P < 0.001), consistent with an immunoreactive and drug-permeable TME. The MagIC-PDX model behavior corresponds to the patient tumor, and the response to the combination treatment showed similar results compared to the murine model. Conclusions: MR001 synergizes with TMZ to exert potent antitumor activity in the murine multiple metastatic melanoma model and MagIC-PDX model. The MagIC-PDX model accurately reproduced patient-like metastatic dissemination. These findings support further development of MR001 based combination therapies and highlight MagIC-PDX as a rapid, patient-relevant platform for preclinical testing and precision modeling.
No takes yet. Share an insight, caveat, or question.
卢士英 et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: